Starting Immunotherapy and Chemo Tomorrow

Options
13»

Comments

  • SpringerSpanielMom
    SpringerSpanielMom Member Posts: 137 Member
    Options

    Is the part about carbo taxol withholding being unethical just now changing? Because someone posted a study on Facebook that is doing frontline immunotherapy instead of frontline carbo taxol for one arm, though as I recall it's only for Stages 3 & 4 cancers (or recurrent, any stage)? Can patients now knowingly take the risk to forego traditional chemo? Appears so. I'll try to track that down.

  • SpringerSpanielMom
    SpringerSpanielMom Member Posts: 137 Member
    Options

    Here it is--Keytruda plus Lenvima v. Carbo Taxol. I was very surprised to see Carbo Taxol (and any chemo) was excluded entirely for half the patients. This must be a brand new thing. https://www.clinicaltrials.gov/ct2/show/NCT03884101 The hypothesis is fascinating, last line especially: "It is hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for progression-free survival (PFS) per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR). It is also hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for overall survival (OS)."

  • TeamT
    TeamT Member Posts: 30 Member
    Options

    I was just repeating what my G/O told me about my particular diagnosis. But yes, at least for me there was counseling and a 28 day window to also do my own research before I signed off on it. Also, you can drop out of the trial anytime you want. So there should be nobody in that trial that hasn't been told what's happening.

  • SpringerSpanielMom
    SpringerSpanielMom Member Posts: 137 Member
    Options

    To TeamT, absolutely. Thanks. I'm so sorry I was unclear. Please bear with me. Your study includes carbo taxol for both arms, which is as you note, standard, and considered ethical. I was just surprised to see this one trial at least that left out carbo/taxol/chemo for half the participants. I think the part about always offering carbo taxol/chemo for both arms and then adding immunotherapy for one half because of ethics was true until something like yesterday morning! They must be getting more confident about immunotherapy, which may help some on this board who are very against carbo taxol and other chemo, for various reasons. I am more neutral; I don't think carbo taxol works very well, but did it, because it's still recommended at this time. I will say others must think CT must not work that well if it's okay for this study to take it off the table. This landscape is changing so fast that it seems impossible to keep up. Enjoyed your posts very much; helping me learn and explore. I am looking for a study that will allow me as a carcinosarcoma/GCS Stage 1A with a low tumor mutation burden, no Lynch, MSS, and wild type P53. All of the studies I found so far are looking for recurrence OR Stages 3-4. Lots of exclusions--for example, the one comparing Keytruda and Lenvima alone to carbo taxol alone specifically excludes MMMT/GCS patients, a common thread that DR. Arend at ALA is trying to change. Yours allows carcinosarcoma patients (yay!) but I would have to be Stages 3-4 or recurrent or both, none of which I am. Because Stage 1As tend to recur for my cancer, I'm looking for therapies to prevent recurrence, something akin to taking tamoxifen or aromatase inhibitors as breast cancer survivors routinely do. Thank you so much.

  • TeamT
    TeamT Member Posts: 30 Member
    Options

    I'm no expert by any means, I really just started participating and learning about what is happening with others. I'm embarrassed to say that I've just been in my own bubble for so long. Lets face it, mine was what I have seen loosely referred to as "Garden Variety Endometrial Cancer" Stage 2 Grade 2. I really didn't think I had anything to contribute. My surgery was relatively normal and I skated through all my radiation treatments with no real side effects.

    And then suddenly, less than 6 months later it went from Garden Variety to Inoperable and Incurable with a median survival of 12-15 months. The doctor did not utter those exact words to me. To her credit, she has never discussed or focused on expiration dates. That's what I have continually found in my own research. She did not correct me however, when I referred to my diagnosis as "grim". It is due to those circumstances that I became eligible for a clinical trial. I'm much more upbeat now, but those first weeks and months were awful. She also told me that I will still have the option for hormonal therapy in the future if necessary. So I do at least still have that option in my pocket.

    I now feel like I have something to contribute and so much to learn. What a club, huh? Thanks for "listening" to me ramble. 😉

  • SpringerSpanielMom
    SpringerSpanielMom Member Posts: 137 Member
    Options

    You're amazing and you have already contributed so much to me. I'm tearing up. I wish you all the best and hope this trial knocks it out! What a club indeed...one where you become a member without even trying and meet some wonderful people...but the dues are really high. :-(

  • SpringerSpanielMom
    SpringerSpanielMom Member Posts: 137 Member
    Options

    Re Stage, I saw elsewhere you were Stage 3. Thanks.

  • bluehyacinth
    bluehyacinth Member Posts: 54 Member
    Options

    I was on Keytruda for 4 1/2 years until all my glands were toast in fact. I started as 3cII and had liver mets grow while on chemo. Surgery 2-15 and I am still here, but I now have type 1 diabetes, hypothyroidism, Cushing etc so don't think Keytruda is without side effects if you are on it long enough, but all good. I got it for free from Merck, no trial for me I was not interested in adding anything to Keytruda.

  • NoTimeForCancer
    NoTimeForCancer Member Posts: 3,371 Member
    Options

    Ginnie, I wish none of us had to learn anything about this disease. Do what you can and please continue to let us know how you are doing.

    Hugs dear one.